Chase

SK Closes Sale of NuCera Solutions to Chase

An affiliate of funds advised by SK Capital Partners has completed the sale of NuCera Solutions to international specialty chemicals company Chase Corp. for $250 million. The companies entered into the agreement on Jul. 18.

News

Allergan Buys US Chase Pharmaceuticals

Top-Feature

CHEManager c/o Wiley-VCH Verlag

Upcoming Virtual Events

Aenova Holding GmbH

Small Molecules: Choosing a Strategic, Scalable, and De-Risked Development Path

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

BIO Deutschland e.V.

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Expert Insights

Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.